Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT00169468 Completed - B Cell Lymphoma Clinical Trials

Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma

Start date: January 2005
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the response rate and toxicity of the association R-CHOP with two schedules of administration of Velcade, in B-cell CD 20 + lymphoma patients, aged from 18 to 80 years The goal is to get a response rate at least at what observed with R-CHOP alone and will be evaluates with a sequential test. The other objective is to evaluate the toxicity

NCT ID: NCT00169208 Completed - Follicular Lymphoma Clinical Trials

Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma

Start date: April 2001
Phase: Phase 2
Study type: Interventional

This study is a multicentric trial evaluating the efficacy of the RFM regimen in patients aged 18 to 75 years with relapsed/refractory follicular non-Hodgkin's lymphoma (NHL).

NCT ID: NCT00169195 Completed - Clinical trials for Diffuse Large Cell Lymphoma

Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma

Start date: April 2003
Phase: Phase 2
Study type: Interventional

The Purpose of this study is to evaluate the efficacy and the safety of R-GEMOX in refractory/relapsed patients with CD20-positive large B-cell lymphoma who are not eligible for autologous transplantation.

NCT ID: NCT00169156 Completed - Clinical trials for Untreated T-cell Angioimmunoblastic Lymphoma

A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma

Start date: December 2005
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and the safety of a front-line treatment combining CHOP regimen and rituximab in patients aged 60 to 80 years with previously untreated AIL.

NCT ID: NCT00169143 Completed - Clinical trials for Untreated CD20-positive Large B-cell Lymphoma

Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma

Start date: May 2004
Phase: Phase 2
Study type: Interventional

Evaluation of the efficacy of a single injection of Pegfilgrastim (6mg) administered at day 3 of each cycle of R-ACVBP regimen during 4 cycles in patients with CD20+ diffuse large B-cell lymphoma presenting at least 2 adverse prognostic factor of the age-adjusted international prognostic index (Aa-IPI).

NCT ID: NCT00169130 Completed - Clinical trials for Lymphoma, Large-Cell, Diffuse

ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma

Start date: October 1999
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective of the study is to evaluate the efficacy of ASCT as consolidation in case of bcl-2 overexpression in non previously treated patients aged 60 years or less with low-intermediate risk diffuse large B-cell lymphoma who responded to ACVBP regimen. Our goal is to obtain a 15% increase of event-free survival at 2 years.

NCT ID: NCT00168740 Completed - Clinical trials for Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma

Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)

Start date: April 1995
Phase: Phase 3
Study type: Interventional

Rituximab is an antibody made in a laboratory. It binds to lymphoma cells and kills them. Treatment of recurrent B-cell lymphoma with rituximab may delay or prevent relapses. A total of 166 patients with recurrent B-cell lymphoma were given intravenous rituximab once a week for 4 weeks. The patients' tumors were measured before and after treatment. Ten patients had a complete response and 70 patients had a partial response to rituximab. The median duration of response was 11.2 months.

NCT ID: NCT00168727 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma

Start date: June 1, 2003
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the safety and effectiveness of a treatment regimen using Zevalin® plus Rituxan® for patients who have low grade Non-Hodgkin's Lymphoma (NHL) or relapsed Non-Hodgkin's lymphoma and have been previously treated. This study will use an experimental scheduling regimen. No chemotherapy will be used in this study.

NCT ID: NCT00166439 Completed - Lymphoma Clinical Trials

Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma

Start date: March 2005
Phase: Phase 2
Study type: Interventional

The goals of this protocol are to determine the effect of oxaliplatin, cytosine arabinoside, and dexamethasone with Rituxan (ROAD) as treatment for patients with relapsed CD20+ B-cell non-Hodgkins lymphoma (NHL).

NCT ID: NCT00163761 Completed - Clinical trials for Non-Hodgkin's Lymphoma

Efficacy Study of Outpatient Therapy for Lymphoma

Start date: December 2002
Phase: Phase 2
Study type: Interventional

This is a Phase II trial evaluating the efficacy (overall response rate) of a risk-adjusted outpatient based approach to lymphoma salvage therapy with vinorelbine, gemcitabine and pegfilgrastim and/or gemcitabine, ifosfamide, vinorelbine and pegfilgrastim.